X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Company lead product candidate EP-104GI (fluticasone propionate). which is being evaluated for the safety and efficacy of EP-104GI as a treatment for patients with eosinophilic esophagitis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Gastroenterology Product Name: EP-104GI
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Details:
The net proceeds will be used in the development of EP-104IAR (fluticasone propionate), which is a GR-agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Osteoarthritis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Musculoskeletal Product Name: EP-104IAR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Raymond James Ltd
Deal Size: $33.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2024
Details:
Eupraxia expects to use the net proceeds to fund research and development activities, including EP-104IAR, a novel, sustained-release, intra-articular (IA) formulation of the corticosteroid fluticasone propionate, being developed for the treatment of Osteoarthritis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Musculoskeletal Product Name: EP-104IAR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Raymond James Ltd
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 11, 2024
Details:
EP-104AR (fluticasone propionate) endeavours to provide long-term pain relief with fewer unwanted side effects for Osteoarthritis patients It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane and Injected into the knee.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Musculoskeletal Product Name: EP-104IAR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
EP-104IAR is composed of fluticasone propionate drug crystals coated with heat-treated polyvinyl alcohol (PVA) to result in extended release properties used in knee osteoarthritis pain.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Musculoskeletal Product Name: EP-104IAR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
